Literature DB >> 20425317

The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Elizabeth Naparstek1.   

Abstract

The addition of rituximab to chemotherapy has substantially changed the treatment strategies for patients with B-cell lymphomas. Rituximab, combined with standard chemotherapy regimens, shows consistently improved results compared with chemotherapy alone and has been extensively employed in both newly diagnosed and relapsed patients with B-cell lymphoma. Because of its low toxicity profile and its potent antilymphoma activity mediated through direct apoptotic and indirect effector mechanisms, rituximab also has been actively incorporated into stem cell transplantation (SCT) protocols to attain a state of minimal disease, provide a safe and effective method for in vivo purging prior to autologous SCT, and promote graft-versus-lymphoma effects in allogeneic SCT. This review compiles the still immature but rapidly growing data on this combined modality.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 20425317     DOI： 10.1007/s11899-006-0003-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  74 in total

1.  A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.

Authors:  M Lazzarino; L Arcaini; P Bernasconi; E P Alessandrino; L Gargantini; R Cairoli; E Orlandi; C Astori; E Brusamolino; G Pagnucco; A A Colombo; S Calatroni; I Iacona; M B Regazzi; E Morra
Journal:  Br J Haematol       Date:  2002-01       Impact factor: 6.998

2.  High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Authors:  Marco Ladetto; Paolo Corradini; Sonia Vallet; Fabio Benedetti; Umberto Vitolo; Maurizio Martelli; Maura Brugiatelli; Paolo Coser; Alessio Perrotti; Ignazio Majolino; Giuseppe Fioritoni; Sergio Morandi; Maurizio Musso; Renato Zambello; Teodoro Chisesi; Nicola Di Renzo; Paolo Vivaldi; Alberto De Crescenzo; Andrea Gallamini; Flavia Salvi; Gino Santini; Carola Boccomini; Marco Sorio; Monica Astolfi; Daniela Drandi; Alessandro Pileri; Corrado Tarella
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 3.  The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma.

Authors:  Koen Van Besien
Journal:  Blood Rev       Date:  2006-03-02       Impact factor: 8.250

4.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

5.  High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

Authors:  Eric Deconinck; Charles Foussard; Noel Milpied; Philippe Bertrand; Patrick Michenet; Pascale Cornillet-LeFebvre; Martine Escoffre-Barbe; Herve Maisonneuve; Vincent Delwail; Remy Gressin; Eric Legouffe; Jean-Pierre Vilque; Bernard Desablens; Jerome Jaubert; Jean-François Ramee; Arash Jenabian; Antoine Thyss; Annick Le Pourhiet-Le Mevel; Philippe Travade; Roselyne Delepine; Philippe Colombat
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

6.  Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8.

Authors:  R Ratei; A Matylis; D Krahl; R Arnold; H Stein; B Dörken; W D Ludwig
Journal:  Leuk Lymphoma       Date:  2000-12

7.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

Authors:  Alessandro M Gianni; Michele Magni; Maurizio Martelli; Massimo Di Nicola; Carmelo Carlo-Stella; Silvana Pilotti; Alessandro Rambaldi; Sergio Cortelazzo; Caterina Patti; Guido Parvis; Fabio Benedetti; Saveria Capria; Paolo Corradini; Corrado Tarella; Tiziano Barbui
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

8.  Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease.

Authors:  Marijke R Canninga-van Dijk; Hanneke M van der Straaten; Rob Fijnheer; Cornelus J Sanders; Jan G van den Tweel; Leo F Verdonck
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

9.  Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.

Authors:  K Belhadj; M-H Delfau-Larue; T Elgnaoui; F Beaujean; J-L Beaumont; C Pautas; I Gaillard; Y Kirova; A Allain; P Gaulard; J-P Farcet; F Reyes; C Haioun
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

10.  Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.

Authors:  Amy L Hoerr; Feng Gao; Josephine Hidalgo; Divya Tiwari; Kristie A Blum; Vikram Mathews; Douglas R Adkins; William Blum; Steven Devine; Ravi Vij; Lawrence T Goodnough; John F Dipersio; Hanna J Khoury
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544
View more
  1 in total

1.  Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.

Authors:  Shingo Nakamoto; Tatsuo Kanda; Chiaki Nakaseko; Emiko Sakaida; Chikako Ohwada; Masahiro Takeuchi; Yusuke Takeda; Naoya Mimura; Tohru Iseki; Shuang Wu; Makoto Arai; Fumio Imazeki; Kengo Saito; Hiroshi Shirasawa; Osamu Yokosuka
Journal:  Int J Mol Sci       Date:  2014-11-21       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.